Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H1 2019
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H1 2019
SUMMARY
According to the recently published report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H1 2019'; Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) pipeline Target constitutes close to 7 molecules.
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Macrophage-stimulating protein receptor is a protein encoded by the MST1R gene. It regulates many physiological processes including cell survival, migration and differentiation. Upon ligand binding at the cell surface it induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules and interacts with the PI3-kinase subunit PIK3R1, PLCG1.
The report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H1 2019' outlays comprehensive information on the Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2 and 1 respectively.
Report covers products from therapy areas Oncology and Metabolic Disorders which include indications Breast Cancer, Gastric Cancer, Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Clear Cell Squamous Cell Carcinoma, Colon Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Lung Cancer, Malignant Neoplasms, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Hodgkin Lymphoma, Osteolytic Bone Metastasis, Osteoporosis, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Rhabdomyosarcoma, Solid Tumor and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H1 2019'; Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) pipeline Target constitutes close to 7 molecules.
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Macrophage-stimulating protein receptor is a protein encoded by the MST1R gene. It regulates many physiological processes including cell survival, migration and differentiation. Upon ligand binding at the cell surface it induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules and interacts with the PI3-kinase subunit PIK3R1, PLCG1.
The report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H1 2019' outlays comprehensive information on the Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2 and 1 respectively.
Report covers products from therapy areas Oncology and Metabolic Disorders which include indications Breast Cancer, Gastric Cancer, Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Clear Cell Squamous Cell Carcinoma, Colon Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Lung Cancer, Malignant Neoplasms, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Hodgkin Lymphoma, Osteolytic Bone Metastasis, Osteoporosis, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Rhabdomyosarcoma, Solid Tumor and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)
- The report reviews Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Overview
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Aslan Pharmaceuticals Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
Lead Discovery Center GmbH
Pfizer Inc
SignalChem Lifesciences Corp
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Drug Profiles
AL-2846 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASLAN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-777607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RON Kinase for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MST1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Dormant Products
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Discontinued Products
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 15, 2018: Crizotinib Plus Radiation May Reduce NF2-Related Hearing Loss
Jul 26, 2018: NICE Issues Technology Appraisal Guidance on Crizotinib for Treating ROS1-positive Advanced NSCLC
Jun 11, 2018: Pfizer’s Xalkori accepted for use in NHS Scotland
Jun 02, 2018: Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer
May 29, 2018: Pfizer's XALKORI (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications
Apr 15, 2018: Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-positive Inflammatory Myofibroblastic Tumor
Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer
Feb 05, 2018: Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2
Dec 08, 2017: Largest trial ever performed in alveolar soft part sarcoma: results published
Nov 14, 2017: XALKORI Approved by Health Canada for the Treatment of Patients with ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sep 20, 2017: Publication of EORTC 90101 “CREATE” Phase II trial
Sep 11, 2017: Pfizer Presents Overall Survival Data of XALKORI in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
Aug 30, 2017: New approach to genetic testing matches lung cancer patient with life-saving drug
Jun 02, 2017: OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer
Feb 15, 2017: ASLAN Pharmaceuticals’ new ASLAN002 (BMS777607) phase 1 data published in Science Translational Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Overview
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Aslan Pharmaceuticals Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
Lead Discovery Center GmbH
Pfizer Inc
SignalChem Lifesciences Corp
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Drug Profiles
AL-2846 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASLAN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-777607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RON Kinase for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MST1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Dormant Products
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Discontinued Products
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 15, 2018: Crizotinib Plus Radiation May Reduce NF2-Related Hearing Loss
Jul 26, 2018: NICE Issues Technology Appraisal Guidance on Crizotinib for Treating ROS1-positive Advanced NSCLC
Jun 11, 2018: Pfizer’s Xalkori accepted for use in NHS Scotland
Jun 02, 2018: Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer
May 29, 2018: Pfizer's XALKORI (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications
Apr 15, 2018: Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-positive Inflammatory Myofibroblastic Tumor
Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer
Feb 05, 2018: Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2
Dec 08, 2017: Largest trial ever performed in alveolar soft part sarcoma: results published
Nov 14, 2017: XALKORI Approved by Health Canada for the Treatment of Patients with ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sep 20, 2017: Publication of EORTC 90101 “CREATE” Phase II trial
Sep 11, 2017: Pfizer Presents Overall Survival Data of XALKORI in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
Aug 30, 2017: New approach to genetic testing matches lung cancer patient with life-saving drug
Jun 02, 2017: OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer
Feb 15, 2017: ASLAN Pharmaceuticals’ new ASLAN002 (BMS777607) phase 1 data published in Science Translational Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Advenchen Laboratories LLC, H1 2019
Pipeline by Aslan Pharmaceuticals Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Eli Lilly and Co, H1 2019
Pipeline by Lead Discovery Center GmbH, H1 2019
Pipeline by Pfizer Inc, H1 2019
Pipeline by SignalChem Lifesciences Corp, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Advenchen Laboratories LLC, H1 2019
Pipeline by Aslan Pharmaceuticals Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Eli Lilly and Co, H1 2019
Pipeline by Lead Discovery Center GmbH, H1 2019
Pipeline by Pfizer Inc, H1 2019
Pipeline by SignalChem Lifesciences Corp, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
COMPANIES MENTIONED
Advenchen Laboratories LLC
Aslan Pharmaceuticals Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
Lead Discovery Center GmbH
Pfizer Inc
SignalChem Lifesciences Corp
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
COMPANIES MENTIONED
Advenchen Laboratories LLC
Aslan Pharmaceuticals Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
Lead Discovery Center GmbH
Pfizer Inc
SignalChem Lifesciences Corp
